Site search
2954 results for '' found
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 [GSK6042981] versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [GIST] after Imat
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 [GSK6042981] versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors [GIST] after Imat
/
Australasian Dermatology Registry (Trial Not Registered)
Australasian Dermatology Registry (Trial Not Registered)
/
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human
/
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 [IDH1]-mutant glioma (NCT05303519)
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 [IDH1]-mutant glioma (NCT05303519)
/
TRANSFORMING EPILEPSY OUTCOMES WITH PERSONALISED DEEP BRAIN STIMULATION AND EXTENDED INTRACRANIAL EVALUATIONS (ACTRN12626000569303)
TRANSFORMING EPILEPSY OUTCOMES WITH PERSONALISED DEEP BRAIN STIMULATION AND EXTENDED INTRACRANIAL EVALUATIONS (ACTRN12626000569303)
/
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
/
Alfred_Health_GP_News_-_June_2026.pdf
Hidden Disability Sunflower continues to grow
About two years on from launching across The Alfred, Caulfield and Sandringham hospitals, HealthSmart Pharmacy at The Alfred is continuing its support of the Hidden Disabilities Sunflower program.
/news/hidden-disability-sunflower-sprouts-new-growth
https://www.advancecareplanning.org.au/professional-resources/professional-considerations/general-practice-considerations#section__supportingadvancecareplanningingeneralpracticeguidanceonmedicarebenefitsscheduleitemuse
Celebrating International Clinical Trials Day 2026
Shaping tomorrow - together. Our researchers are working towards a better healthcare future for all, hear what they want you to know about clinical trials.
/news/celebrating-international-clinical-trials-day-2026